Navigation Links
Operational research seeks benefit for stroke victims
Date:2/15/2012

Researchers from the University of Exeter, Peninsula College of Medicine and Dentistry (PCMD), are working with clinicians from the South Western Ambulance Service NHS Foundation Trust (SWASFT) and the Royal Devon & Exeter Hospital NHS Foundation Trust (RD&E) to reduce the time it takes from the start of a stroke to the administration of vital clot-busting drug treatment.

The researchers are from the PCMD-based National Institute for Health Research (NIHR) Peninsula Collaboration for Health, Operational Research and Development (PenCHORD), which is part of the NIHR Peninsula Collaboration for Leadership and Applied Health Research and Care (PenCLAHRC).

The study is investigating the whole process of emergency treatment that follows when a person suffers an acute stroke from a blocked artery in the brain. For most patients in this situation, the earliest possible administration of the clot-busting drug Alteplase can greatly improve their chances of recovery called thrombolysis. The drug is currently licensed for delivery up to three hours from the onset of a stroke, but in that time the patient needs to call an ambulance, get to hospital, have a brain scan, and be assessed by specialists before receiving the treatment.

The research team is working with healthcare professionals from SWASFT and the RD&E to analyse the various steps by which a stroke patient is identified, transported to hospital and treated. This includes paramedics, the emergency department (ED) team, triage nurses, the acute stroke team and the radiology department (which performs the brain scans).

By investigating what happens 'on the ground', researchers have been able to create computer simulations that imitate the various permutations of stroke victim identification, transport, arrival at hospital and treatment.

The computer model takes into account the number and level of healthcare professionals involved with each case, the time of day or night, and the 'busy-ness' of the various hospital departments involved in the treatment process.

Their analysis of over 1400 episodes of care has enabled them to identify the bottlenecks in the system, and take steps to speed up the process of emergency care which can lead to earlier clot-busting treatment. The researchers estimate that the number of people whose stroke could be greatly improved by earlier treatment could treble.

The research has already led to the introduction of a pilot for early referral to the acute stroke team at the moment the ambulance arrives at the ED. The pilot was introduced in December 2011 and early figures already show that the changes have led to a doubling of the number of patients admitted with acute stroke receiving clot-busting treatment within the three hour window (the national average is just five per cent: the national target is 10 per cent).

The research team is currently working on a thorough evaluation of the pilot scheme, as well as developing a mobile phone referral method that ambulance crews can use to inform the stroke team that a patient is on their way so reducing the time the patient spends in the ED before receiving thrombolysis.

Professor Stuart Logan, Director of PenCLAHRC, commented: "This project shows just how powerful close collaboration between academics, clinicians and managers can improve patient outcome. Research can sometimes feel like a luxury, this is the kind of work that reminds us of why with proper partnerships can have immediate impact. We look forward to the next stages of the study, which has the potential for major impact nationally and internationally."

Dr Martin James, Consultant Physician and Lead Clinician for Stroke at the RD&E said: "Our work with academic researchers in PenCHORD to build the computer simulation has been a great example of the NHS collaborating with Universities to improve care. Using the simulation has enabled us to identify and unblock the bottlenecks in getting the treatment to patients much more quickly than we could in the past. What used to takes us months or even years of trial and error can be accomplished in an afternoon using the simulation. This means that research findings can be applied to the care of patients much more quickly, and reduce the misery of disability after a stroke, which is what these collaborations are all about."

James Wenman, the Clinical Development Manager for the South Western Ambulance Service NHS Foundation Trust said, "We are delighted to be working in partnership with the Peninsula College of Medicine and Dentistry, and our colleagues at the RD&E on this important project. Improving the services we provide to patients who have experienced a stroke is a key priority for SWASFT. The sooner patients receive treatment, the greater their chance of survival, which means they are more likely to make a full recovery. The Trust aims to deliver the right care in the right place at the right time, and this initiative will undoubtedly help us to achieve this in our ongoing quest to save lives."


'/>"/>
Contact: Andrew Gould
andrew.gould@pcmd.ac.uk
139-268-6107
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. CellTrak Technologies Inc. Wins Prestigious I Award for Operational Effectiveness
2. MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans
3. Lumension Unveils Intelligent Application Whitelisting that Operationalizes a Proactive Endpoint Security Approach
4. GW researchers reveal digital transcriptome of breast cancer
5. PRP treatment aids healing of elbow injuries say researchers
6. Helmet fit critical to preventing concussion, say researchers
7. Pot Use Could Double Risk of Car Crash, Research Shows
8. Rothman at Jefferson researchers show benefits of local anesthesia after knee replacement surgery
9. Researchers find important target playing role in tobacco-related lung cancers
10. Heavy lifting for cancer research
11. Boston University research suggests new pathways for cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... Laguna Hills, CA (PRWEB) , ... March 23, ... ... in document management and workflow solutions, today named The Resource Group as their ... annual customer and partner conference in Newport Beach, CA. The award recognizes ...
(Date:3/23/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon ... talked on her program about how she is looking forward to World Water Day ... important distinction. World Water Day, Kleyne pointed out, is an occasion for looking ahead ...
(Date:3/23/2017)... , ... March 23, 2017 , ... It’s that time ... many students are thinking about summer internships , which can be frustrating when ... The pros at Garden Media Group, a boutique public relations firm outside of Philadelphia, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: